JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng
Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most promising salvage treatments for relapsed/refractory large B-cell lymphoma (r/r LBCL), offering durable remission for about one-third of patients. However, the remaining two-thirds either fail to respond to CAR-T therapy or experience relapse, resulting in poor survival outcomes. This underscores the urgent need to explore methods to enhance the efficacy of CAR-T therapy.
